Immunic Therapeutics

📢 TOMORROW's the day! Don’t miss our Multiple Sclerosis R&D Day in New York City! 🗽 Explore how vidofludimus calcium, our Nurr1 activator, could potentially change the future of multiple sclerosis treatment. 🕥 10:30 am - 12:30 pm ET (networking lunch to follow) 📍 One Five One, 151 West 42nd Street, New York, NY 10036 🔬 Join top MS experts Dr. Francesca Montarolo and Dr. Amit Bar-Or, along with the Immunic management team, for insightful presentations. ➡️ Last chance to RSVP: [email protected] #MS #MultipleSclerosis #MSResearch #Nurr1 #DHODH #vidofludimus #IMU838 #IMUX #Immunic #Networking #NYC

🧬 Immunic at EUROTOX 2024 🧬 We are pleased to share that Juliano R. Fonseca, PhD, our Head of Preclinical Development, will attend the 58th Congress of the European Societies of Toxicology in Copenhagen, Denmark taking place September 8-11. This event brings together experts to discuss the latest advances in toxicology, reflecting Immunic’s commitment to innovative and safe drug development. EUROTOX Congress #EUROTOX2024 #EUROTOX #Toxicology #Immunic #IMUX

🌟 September marks a special milestone for our colleague Mehrangez Khasanova, who celebrates her 5th anniversary at Immunic! 🎉 Ever since starting her journey at IMUX, Mehrangez has consistently demonstrated her dedication, professionalism, and heart. We are so proud of your growth and all the contributions you have made over the years, Mehrangez. Here's to many more years of success together! 🙌 #CareerMilestone #ColleagueAppreciation #Immunic #IMUX

📢 Dr. Martina Wirth, Senior Manager Translational Pharmacology at Immunic, will be presenting data from our phase 1b clinical trial of IMU-856 in a late-breaking poster presentation at the 20th International Celiac Disease Symposium (ICDS) in Sheffield, UK. 🇬🇧 🗓️ When? Friday, September 6, 10-11am BST 📍 Where? Posterboard 4, poster number: 263 🌾 Title: First-In-Human Trial of IMU-856, an Orally Available Epigenetic Modulator of Barrier Function and Regeneration for the Treatment of Celiac Disease 💙 IMU-856 is an orally available, systemically acting small molecule modulator targeting SIRT6, designed to restore intestinal barrier function and promote regeneration of the bowel epithelium in patients with celiac disease and other gastrointestinal disorders. #CeliacDisease #Celiac #Gastroenterology #Pharmacology #IMUX #Immunic #IMU856 #SIRT6

🚨 We are excited to share that the first patient has been enrolled in an investigator-sponsored phase 2 clinical trial of vidofludimus calcium for post-COVID syndrome, sponsored by Goethe University Frankfurt and funded by a German government grant. 💊 We are proud to provide the study drug, vidofludimus calcium, which is being tested not only for its potential to alleviate severe post-COVID fatigue but also for its ability to suppress Epstein-Barr virus reactivation - a suspected cause of this fatigue.  🧠 This study could also have a potential read-through to our multiple sclerosis development program. MS patients suffer from similar debilitating fatigue symptoms, for which currently no effective therapies are available. 💪 ➡️ Learn more: https://bit.ly/4gfmgkX Universitätsmedizin Frankfurt #Immunic #IMUX #vidofludimus #IMU838 #PostCOVID #PCS #fatigue #EpsteinBarr #EBV #MultipleSclerosis #MS #MSResearch #ClinicalTrials

📢 Mark your calendars for our Multiple Sclerosis R&D Day in New York City! 🗽 Discover how vidofludimus calcium, our Nurr1 activator, could potentially revolutionize multiple sclerosis treatment. 🗓️ Tuesday, September 10, 2024 🕥 10:30 am - 12:30 pm ET (networking lunch to follow) 📍One Five One, 151 West 42nd Street, New York, NY 10036 🔬 Don't miss the presentations from the top MS experts, Dr. Francesca Montarolo and Dr. Amit Bar-Or, alongside the Immunic management team. ➡️ RSVP by emailing: [email protected] #MultipleSclerosis #MS #MSResearch #Vidofludimus #Nurr1 #IMU838 #Immunic #IMUX #Networking #NewYork

📢 Juliano R. Fonseca, PhD, Head of Preclinical Development at Immunic, will present data from a phase 1, open-label mass balance and pharmacokinetics study of our lead asset at the DMDG 50th Open Meeting 2024 taking place September 2-4 in York, UK. 🇬🇧 His poster #31 will be available to view the entire length of the meeting, and is accessible on our website: https://bit.ly/3w1Wvzi. #DMDG #Immunic #IMUX #Vidofludimus #IMU838 #pharmacokinetics #Preclinical #ClinicalTrial

👩🔬September is Women in Medicine Month 👩⚕️ 🩺This month, we acknowledge the exceptional women who are making strides in the healthcare and biotechnology space. Their innovation, leadership, and commitment are helping to shape the future of medicine. ♀️ 💪 At Immunic, we are proud to work alongside such femal pioneers who are driving progress and expanding the possibilities of science. Here's to all the women in medicine - your impact is significant! 🔬 #WIMMonth #WomenofAMA #WomenInMedicine #FemalePower #healthcare #biotechnology #medicine #science #Immunic #IMUX #WeLoveTheBeautyOfScience

🔭 August is winding down and as we look forward to September, we are thrilled to give you a sneak peek into an exciting event! 🧠 Join us at the ECTRIMS congress taking place September 17-20 in Copenhagen, Denmark, where we will be showcasing our 🎗️multiple scerlosis research. Visit our booth #60 for more insights and a chance to meet our dedicated MS team. See you in 🇩🇰! #ECTRIMS #ECTRIMS2024 #Copenhagen #Denmark #MultipleSclerosis #MS #Vidofludimus #IMU838 #Immunic #IMUX

🤝 Meet the Immunic team at the following events and conferences in September: 🇺🇸 September 10: Immunic’s Multiple Sclerosis R&D Day in New York City, USA 🇩🇰 September 18-20: 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark 🇬🇧September 2-4: DMDG 50th Open Meeting 2024 in York, United Kingdom 🇬🇧 September 5-7: 20th International Celiac Disease Symposium ICDS in in Sheffield, United Kingdom 🇺🇸 September 17-19: 2024 Cantor Fitzgerald Global Healthcare Conference in New York City, USA ➡️ https://bit.ly/3YYm8QB ECTRIMS #ECTRIMS #ECTRIMS2024 #DMDG Cantor Fitzgerald #IMUX #Immunic #MS #MultipleSclerosis #Vidofludimus #PMS #RMS #biotechnology #healthcare